Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Operating Expenses (2016 - 2025)

Integra Lifesciences Holdings' Operating Expenses history spans 17 years, with the latest figure at $411.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 1.2% year-over-year to $411.9 million; the TTM value through Dec 2025 reached $2.1 billion, up 34.54%, while the annual FY2025 figure was $2.1 billion, 34.54% up from the prior year.
  • Operating Expenses for Q4 2025 was $411.9 million at Integra Lifesciences Holdings, up from $390.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $928.3 million in Q2 2025 and bottomed at $320.1 million in Q3 2022.
  • The 5-year median for Operating Expenses is $358.4 million (2023), against an average of $390.2 million.
  • The largest annual shift saw Operating Expenses decreased 4.93% in 2022 before it soared 120.39% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $347.3 million in 2021, then dropped by 4.93% to $330.2 million in 2022, then grew by 9.33% to $361.0 million in 2023, then increased by 12.75% to $407.0 million in 2024, then rose by 1.2% to $411.9 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Operating Expenses are $411.9 million (Q4 2025), $390.3 million (Q3 2025), and $928.3 million (Q2 2025).